development second-generation antiandrogen treatment advanced prostate cancer
metastatic prostate cancer treated drugs antagonize androgen action patients progress aggressive form disease called castration-resistant prostate cancer driven elevated expression androgen receptor characterize diarylthiohydantoins rd162 mdv3100 two compounds optimized screen nonsteroidal antiandrogens retain activity setting increased androgen receptor expression compounds bind androgen receptor greater relative affinity clinically used antiandrogen bicalutamide reduce efficiency nuclear translocation impair dna binding androgen response elements recruitment coactivators rd162 mdv3100 orally available induce tumor regression mouse models castration-resistant human prostate cancer first patients treated mdv3100 phase i/ii clinical trial % showed sustained declines >% serum concentrations prostate-specific antigen biomarker prostate cancer compounds thus appear promising candidates treatment advanced prostate cancer
